Hi, typically customers use a scale during gravity loading of the bags. CryoMACS was designed with concentrations of 20% or less DMSO in mind. However, the bags have been demonstrated to be DMSO resistant even at room temperature with 100% DMSO. If you need further help, please contact our Global Technical Support Specialists under [email protected]

Hi, the MACSQuant directly not, but if you want you can get more information to your MACSQuant Dx system. Here you find more information to our product www.miltenyibiotec.com/products/macsquant-dx.html

I think u have to use the plant Nuclei extraction you have to use tris HCl 0•4 M pH 7.5, always with ice bath and filter pores 20 micrometers this protocole is used for Allium cepa roots

Our Nuclei Extraction Buffer (130-128-024) has been validated for a wide range of fresh and frozen mouse and human tissues. We have not tested the Nuclei Extraction Buffer on fungal culture, I am afraid. However, we think that the buffer may be applicable to a wide range of species.

@@Miltenyi_Biotec thank you for the information

Glad you liked it!!

Hello, please contact our sales and order team [email protected]

During a manual magnetic cell separation, the negative fraction will drip by gravity and it is necessary to perform the 3 washing step and to collect them as well as part of the negative fraction. Hope, we could help you with this. If you need further help, please contact your technical support [email protected]

Good morning, if you want further information about our Sample Preparation portfolio, please visit our website: www.miltenyibiotec.com/products/macs-sample-preparation.html?query=:relevance:allCategoriesOR:10000088%23OnJlbGV2YW5jZTphbGxDYXRlZ29yaWVzT1I6MTAwMDAwODg%3D

Hello Nolab, maybe we can help you with further information on our website or you also can contact your Support Team Miltenyi Biotec Technical Support Global <[email protected]> www.miltenyibiotec.com/DE-en/lp/immunogenicity-assays-in-drug-discovery/solutions-for-predictive-immunogenicity-assays.html

Thank you for the question. NK cell-based therapeutic strategies in chronic lymphocytic leukemia (CLL) and in other malignancies aim to potentiate and/or restore NK cell activity or to provide patients with functional NK cells able to kill tumor cells. According to Sportoletti et al (NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications - PMC (nih.gov)) ‘’in vitro studies have shown that allogeneic NK cells, after expansion/activation with an optimized protocol, are able to kill CLL cells independently of KIR-HLA mismatches. However, although allogeneic NK cells do not mediate the GvL effect in a CLL-HSCT transplantation setting, they, unlike T cells, lack the potential to cause graft-versus-host disease (GvHD) thus representing appealing and safe candidates for adoptive immunotherapy for CLL.” Your Miltenyi Team

thats a mouse brain lol

Hello INGSOC, to our knowledge and according to the published references there are some clinical trials using NK cells in combination with other drugs treating esophagus cancer. Here you find the references: www.ncbi.nlm.nih.gov/pmc/articles/PMC8113860/ and www.ncbi.nlm.nih.gov/pmc/articles/PMC8630679/#!po=20.7692 Your Miltenyi Support Team.

Hello streunekater, why is it very confusing. Can we might help you in answering any question to our webinar? Sincerely, your Miltenyi KZbin Team